Paclitaxel administration in a patient with hyperbilirubinemia

• Autores: Fernando do Pazo Oubiña, P. Amorós Reboredo, C. Bastida Fernández, Natalia Creus Baró
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 16, Nº. 5, 2014, págs. 9-9
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • A 44-year-old woman diagnosed with invasive lobular breast carcinoma stage IV (bone and liver metastases), was prescribed second line chemotherapy with the scheme carboplatin AUC-2 and paclitaxel 80 mg/m2 days 1, 8 and 15 every 21 days. Baseline total serum bilirubin was 6.9 mg/dL (normal range 0.2-1.2 mg/dL) and direct bilirubin 5.9 mg/dL (normal range <0.6 mg/dL), so paclitaxel dose was reduced to 50%. Seven doses of chemotherapy were administered and total bilirubin levels decreased down to 1 mg/dL. As previous studies suggest, reducing paclitaxel dose to 50% appears to be safe in patients with hyperbilirubinemia due to hepatic tumor involvement